Capricor Therapeutics (CAPR) Competitors $9.64 -0.18 (-1.83%) As of 04/16/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPR vs. HRMY, DVAX, GLPG, CNTA, AGIO, KNSA, ANIP, JANX, MNKD, and ARWRShould you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Harmony Biosciences (HRMY), Dynavax Technologies (DVAX), Galapagos (GLPG), Centessa Pharmaceuticals (CNTA), Agios Pharmaceuticals (AGIO), Kiniksa Pharmaceuticals (KNSA), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), MannKind (MNKD), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical preparations" industry. Capricor Therapeutics vs. Harmony Biosciences Dynavax Technologies Galapagos Centessa Pharmaceuticals Agios Pharmaceuticals Kiniksa Pharmaceuticals ANI Pharmaceuticals Janux Therapeutics MannKind Arrowhead Pharmaceuticals Capricor Therapeutics (NASDAQ:CAPR) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Does the media prefer CAPR or HRMY? In the previous week, Harmony Biosciences had 4 more articles in the media than Capricor Therapeutics. MarketBeat recorded 7 mentions for Harmony Biosciences and 3 mentions for Capricor Therapeutics. Harmony Biosciences' average media sentiment score of 1.36 beat Capricor Therapeutics' score of 1.33 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, CAPR or HRMY? Harmony Biosciences has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapricor Therapeutics$22.27M19.77-$22.29M-$1.20-8.03Harmony Biosciences$714.73M2.24$128.85M$2.5111.13 Is CAPR or HRMY more profitable? Harmony Biosciences has a net margin of 17.98% compared to Capricor Therapeutics' net margin of -146.86%. Harmony Biosciences' return on equity of 23.16% beat Capricor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Capricor Therapeutics-146.86% -112.95% -57.00% Harmony Biosciences 17.98%23.16%14.24% Which has more volatility & risk, CAPR or HRMY? Capricor Therapeutics has a beta of 4.65, indicating that its stock price is 365% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Do analysts rate CAPR or HRMY? Capricor Therapeutics currently has a consensus target price of $34.50, suggesting a potential upside of 257.88%. Harmony Biosciences has a consensus target price of $53.33, suggesting a potential upside of 90.89%. Given Capricor Therapeutics' higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Harmony Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of CAPR or HRMY? 21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 12.0% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor CAPR or HRMY? Capricor Therapeutics received 295 more outperform votes than Harmony Biosciences when rated by MarketBeat users. However, 70.97% of users gave Harmony Biosciences an outperform vote while only 63.78% of users gave Capricor Therapeutics an outperform vote. CompanyUnderperformOutperformCapricor TherapeuticsOutperform Votes36163.78% Underperform Votes20536.22% Harmony BiosciencesOutperform Votes6670.97% Underperform Votes2729.03% SummaryHarmony Biosciences beats Capricor Therapeutics on 13 of the 17 factors compared between the two stocks. Remove Ads Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPR vs. The Competition Export to ExcelMetricCapricor TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$440.33M$6.26B$5.28B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-9.096.6921.6917.68Price / Sales19.77222.71372.8092.89Price / CashN/A65.6738.1534.64Price / Book13.215.776.353.94Net Income-$22.29M$142.01M$3.20B$247.45M7 Day Performance8.56%5.79%3.92%3.17%1 Month Performance-25.16%-15.47%-10.36%-8.53%1 Year Performance73.69%-10.99%10.27%0.32% Capricor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPRCapricor Therapeutics1.8461 of 5 stars$9.64-1.8%$34.50+257.9%+62.6%$440.33M$22.27M-9.09N/APositive NewsHRMYHarmony Biosciences4.5977 of 5 stars$28.40-2.9%$53.33+87.8%-6.2%$1.63B$714.73M13.46200Short Interest ↓Positive NewsDVAXDynavax Technologies4.3328 of 5 stars$12.49-1.3%$21.50+72.1%-7.3%$1.55B$277.25M69.39350News CoverageGLPGGalapagos0.6542 of 5 stars$23.04-3.0%$25.33+10.0%-16.9%$1.52B$275.65M0.001,123Upcoming EarningsHigh Trading VolumeCNTACentessa Pharmaceuticals2.9165 of 5 stars$11.28-3.4%$27.71+145.7%+7.3%$1.50B$6.85M-7.37200Positive NewsHigh Trading VolumeAGIOAgios Pharmaceuticals3.8596 of 5 stars$25.90+0.5%$56.57+118.4%-5.8%$1.48B$36.50M2.28390Analyst RevisionKNSAKiniksa Pharmaceuticals2.4422 of 5 stars$20.28-0.4%$37.17+83.3%+17.6%$1.47B$423.24M-144.85220Upcoming EarningsAnalyst ForecastInsider TradeNews CoverageHigh Trading VolumeANIPANI Pharmaceuticals3.4968 of 5 stars$66.99-0.8%$79.75+19.0%+5.6%$1.46B$614.38M-121.80600Analyst UpgradeHigh Trading VolumeJANXJanux Therapeutics2.6913 of 5 stars$24.38-5.4%$92.44+279.2%-43.2%$1.44B$10.59M-20.8430Gap DownHigh Trading VolumeMNKDMannKind2.2592 of 5 stars$4.69-1.1%$9.21+96.5%+11.9%$1.43B$285.50M67.00400ARWRArrowhead Pharmaceuticals3.4104 of 5 stars$10.25-4.0%$41.44+304.3%-52.0%$1.41B$2.50M-1.98400News CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies HRMY Competitors DVAX Competitors GLPG Competitors CNTA Competitors AGIO Competitors KNSA Competitors ANIP Competitors JANX Competitors MNKD Competitors ARWR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPR) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CAPR Stock Free CAPR Stock Alerts